-
-
-
-
-
-
-
Lake Street on Monopar Therapeutics (MNPR): attractive risk/reward entry point
-
-
-
-
-
-
-
BTIG on Monopar Therapeutics (MNPR): '2026 is expected to be a big year'
-
-
-
-
-
-
-
Barclays Starts Monopar Therapeutics (MNPR) at Overweight
-
-
-
-
-
-
-
Monopar reports ALXN1840 improves copper balance in Wilson disease study
-
-
-
-
-
-
-
Monopar Therapeutics (MNPR) PT Lowered to $52 at Brookline Capital Markets
-
-
-
-
-
-
-
Piper Sandler Starts Monopar Therapeutics (MNPR) at Overweight
-
-
-
-
-
-
-
Monopar Therapeutics (MNPR) Announces Agreement with Alexion, AstraZeneca Rare Disease For Late-Stage Wilson Disease Drug Candidate
-
430,616 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

